Thursday 22 December 2016

New multiple sclerosis drug hailed as a 'landmark'

Ocrelizumab kills the cells that assault the myelin sheath and cause nerve damage

Related items from OnMedica

NHS England loses appeal over PreP drugs
Experts call on regulators to revisit nalmefene decision
75% of reappraised CDF drugs approved for NHS
NICE approves extra ‘triple therapy’ drug for diabetes
Antibiotic prescribing continues to spiral
via OnMedica News Read More Here..

No comments:

Post a Comment